Combination inhaled steroid and long-acting beta₂-agonist in addition to tiotropium versus tiotropium or combination alone for chronic obstructive pulmonary disease

Pharmacology, Toxicology and Pharmaceutical Science

• Adverse Event 100%
• Chronic Obstructive Lung Disease 100%
• Combination Therapy 100%
• Beta Adrenergic Receptor Stimulating Agent 100%
• Steroid 100%
• Placebo 50%
• Beta2 Agonist 50%
• Corticosteroid 50%
• Diseases 25%
• Randomized Controlled Trial 25%
• Bronchodilating Agent 25%
• Number Needed to Treat 25%
• Pneumonia 25%
• Adverse Effect 25%

Keyphrases

• Chronic Obstructive Pulmonary Disease 100%
• Long-acting beta-agonists 100%
• Tiotropium 100%
• Intranasal Steroids 100%
• 95% Confidence Interval 31%
• Odds Ratio 18%
• Combination Therapy 18%
• Combined Therapy 18%
• Lung Function 9%
• Adverse Events 9%
• Placebo 9%
• Long-acting β2-agonist 9%
• Inhaled Corticosteroids 9%
• Statistically Significant Difference 9%
• Quality of Life 4%
• World Health Organization 4%
• Health-related Quality of Life 4%
• Adverse Effects 4%
• Cochrane 4%
• Low Risk 4%
• Serious Adverse Events 4%
• Mechanism of Action 4%
• Randomized Controlled Trial 4%
• Risk of Bias 4%
• Exercise Tolerance 4%
• Pneumonia 4%
• ClinicalTrials.gov 4%
• Airway 4%
• Hospital Admission 4%
• Maintenance Treatment 4%
• Undesirable Effects 4%
• Relative Effect 4%
• St. George's Respiratory Questionnaire 4%
• Life Functioning 4%
• Trial Outcomes 4%
• All-cause Hospitalization 4%
• Global Guidance 4%
• Beneficial Outcomes 4%
• Triple Therapy 4%
• Non-fatal 4%
• Fatal Adverse Events 4%
• Trial Quality 4%
• Long-acting Bronchodilators 4%
• Peto Odds Ratio 4%
• Disease-specific Quality of Life 4%
• Extracted Data 4%
• Number-needed-to-treat 4%
• Single Inhaler 4%
• Average Benefit 4%